Stereotaxis Initiates HEAL HF Clinical Trial

... Stereotaxis, Inc. (Nasdaq: STXS) announced today that it has initiated the HEAL HF clinical trial, which is designed to evaluate the ability to magnetically navigate to multiple potential pacing sites and then optimize LV lead placement to treat heart failure. Professor Carlo Pappone M.D., Ph.D. is the first investigator to successfully enroll patients in the HEAL HF study. [click link for full article] ...